#KPRX

🅱🅸🅶🅾🆁🆁🅴.🅾🆁🅶

@bigorre-org.mastodon.social.ap.brid.gy

13 hours ago

Cox Field airport in Paris (United State) aviation weather and informations KPRX PRX Aviation weather with TAF and METAR, Maps, hotels and aeronautical information for Cox Field airport in Paris (United State)

How many runways can you see for Cox Field airport in Paris area (USA) ? : The answer is on https://www.bigorre.org/aero/meteo/kprx/en #coxfieldairport #airport #paris #usa #kprx #prx #aviation #avgeek vl

🅱🅸🅶🅾🆁🆁🅴.🅾🆁🅶

@bigorre-org.mastodon.social.ap.brid.gy

1 month ago

Aviation weather for Cox Field airport in Paris area (USA) is “KPRX 071755Z AUTO 13011KT 10SM CLR 16/02 A3031 RMK AO2 SLPNO 6//// T01610017 10161 20050 50000” : See what it means on https://www.bigorre.org/aero/meteo/kprx/en #coxfieldairport #airport #paris #usa #kprx #prx #metar #aviation […]

StockTitan

@stocktitan.net

3 months ago

Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds Kiora Pharmaceuticals (NASDAQ: KPRX) announced that the U.S. Patent and Trademark Office issued U.S. patent US-12,472,263 on December 1, 2025 covering additional, novel formulations of the KIO-100 family, including a specific formulation of the API in KIO-104.The API in KIO-104 is a non-steroidal DHODH inhibitor formulated for local retinal delivery. The company is actively screening and dosing in the multicenter Phase 2 KLARITY trial, enrolling up to 28 patients across retinal inflammatory conditions including posterior non-infectious uveitis and diabetic macular edema. KIO-104 previously demonstrated clinical proof-of-concept in a Phase 1 trial in non-infectious uveitis.

#KPRX Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds

www.stocktitan.net/news/KPRX/kiora-pharmace...

StockTitan

@stocktitan.net

4 months ago

Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced third quarter 2025 financial results and provided an update on its pipeline of small molecules for the treatment of retinal diseases. Key third quarter

#KPRX Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases

www.stocktitan.net/news/KPRX/kiora-pharmace...

Small Cap Strategist

@smcapstrategist.bsky.social

4 months ago

Small-cap stocks in new ADX downtrend, Thu Nov 6th - #FTFT #GYRE #HTLD #DMLP #CVAC #INGN #JSPR #BHST #KPRX #MXCT #AIOT #WDH #SITC #NPB #NOTE #MED #JBI #DEA #CNMD #BLND #SGN #KAPA #UAVS #VVPR #TRNS #RPD #PSEC - More: crystalequityresearch.com/trade-alerts... - #smallcap

StockTitan

@stocktitan.net

4 months ago

Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders Kiora Pharmaceuticals (NASDAQ: KPRX) announced on October 30, 2025 that it joined Global Genes' RARE-X Vision Consortium, a corporate‑nonprofit collaboration to accelerate research and development of therapies for rare ocular disorders.The consortium will build a de‑identified, individual‑level global data repository to support patient identification and recruitment, define meaningful outcome measures by aggregating functional, structural, and patient‑reported data, and promote inclusive study design with patient input. Kiora's CEO, Brian Strem, said the collaboration aims to increase the probability of advancing Kiora's experimental inherited retinal disease therapy toward patients.

#KPRX Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders

www.stocktitan.net/news/KPRX/kiora-pharmace...

StockTitan

@stocktitan.net

7 months ago

Kiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal Diseases Kiora Pharmaceuticals (NASDAQ: KPRX) reported Q2 2025 financial results and pipeline updates for retinal disease treatments. The company initiated two Phase 2 clinical trials: KLARITY for KIO-104 (retinal inflammation) and ABACUS-2 for KIO-301 (retinitis pigmentosa). Kiora secured a potential $110M partnership with Senju Pharmaceutical for KIO-301 development in Asia.Financial highlights include a $20.7M cash position, with additional $2.4M in collaboration receivables and $0.7M in tax credits. The company reported a net loss of $2.2M in Q2 2025, unchanged from Q2 2024. R&D expenses increased to $2.6M (before $1.7M in reimbursements), while G&A expenses decreased to $1.4M. Cash runway extends into late 2027, beyond anticipated clinical trial readouts.

#KPRX Kiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal Diseases

www.stocktitan.net/news/KPRX/kiora-pharmace...

🅱🅸🅶🅾🆁🆁🅴.🅾🆁🅶

@bigorre-org.mastodon.social.ap.brid.gy

7 months ago

Cox Field airport in Paris (United State) aviation weather and informations KPRX PRX Aviation weather with TAF and METAR, Maps, hotels and aeronautical information for Cox Field airport in Paris (United State)

How many runways can you see for Cox Field airport in Paris area (USA) ? : The answer is on https://www.bigorre.org/aero/meteo/kprx/en #paris #usa #coxfieldairport #kprx #prx #airport #aviation #avgeek vl

StockTitan

@stocktitan.net

7 months ago

Kiora Pharmaceuticals Granted U.S. Patent Expanding Protection for KIO-104 in the Treatment of Ocular Disease Kiora Pharmaceuticals (NASDAQ: KPRX) has been granted US Patent No. 12,364,680 for KIO-104, expanding its protection for treating various ocular diseases. The patent covers treatment applications including ocular inflammation, uveitis, age-related macular degeneration, and refractive surgery complications, extending market exclusivity until 2043.The company is currently conducting a Phase 2 clinical trial (KLARITY study) investigating KIO-104 in up to 28 patients at two dose levels for inflammatory retinal diseases, including posterior non-infectious uveitis and diabetic macular edema. KIO-104 functions by inhibiting the DHODH enzyme, reducing T-cell replication and inflammation.

#KPRX Kiora Pharmaceuticals Granted U.S. Patent Expanding Protection for KIO-104 in the Treatment of Ocular Disease

www.stocktitan.net/news/KPRX/kiora-pharmace...

Small Cap Strategist

@smcapstrategist.bsky.social

9 months ago

Small-cap stocks with improving money flow, Tues Jun 3rd - #ACMR #BMEA #CCB #ENUX #FONR #HOFT #IMAB #KPRX #MESO #NGNE #PLUS #VET #UTZ #TIXT #SRI #PKST #OLP #NTB #LXU #EXK #CNNE #BLND #XMTR #VRA #UCTT #SPWH - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Grumpy10

@grumpy10.bsky.social

9 months ago

MAG 8 Momentum: NIVF, TRAW, KPRX, PNPN.V $3 Undercard Surge – More Stocks Inside! Getting your Trinity Audio player ready... From $30 million Solana, Bitcoin staking and rare cancer breakthroughs to critical minerals exploration and transformative mergers, these companies—are resha...

#NIVF, #TRAW, #KPRX #PNPNF #PNPN
thestreetreports.com/mag-8-moment...

StockTitan

@stocktitan.net

9 months ago

Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia Kiora Pharmaceuticals (NASDAQ: KPRX) has granted Senju Pharmaceutical an exclusive option for the development and commercialization of KIO-301, a molecular photoswitch therapy for retinal diseases, in key Asian markets including Japan and China. The deal has a potential value of $110 million plus royalties, starting with an immediate $1.25 million option fee. If exercised, Kiora will receive an additional mid-single digit million upfront payment plus development, regulatory, and commercial milestones. This agreement complements Kiora's existing partnership with Théa Open Innovation for markets outside Asia, bringing the total potential value of strategic partnerships to over $400 million plus royalties. KIO-301 is currently in the ABACUS-2 Phase 2 clinical trial, targeting 36 patients with ultra-low vision or no light perception due to retinitis pigmentosa. The therapy aims to restore visual function by targeting surviving retinal ganglion cells.

#KPRX Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia

www.stocktitan.net/news/KPRX/kiora-pharmace...

🅱🅸🅶🅾🆁🆁🅴.🅾🆁🅶

@bigorre-org.mastodon.social.ap.brid.gy

9 months ago

Cox Field airport in Paris (United State) aviation weather and informations KPRX PRX Aviation weather with TAF and METAR, Maps, hotels and aeronautical information for Cox Field airport in Paris (United State)

How many runways do you see for Cox Field airport in Paris area (USA) ? : The answer is on https://www.bigorre.org/aero/meteo/kprx/en #paris #usa #coxfieldairport #kprx #prx #airport #aviation #avgeek vl

StockTitan

@stocktitan.net

10 months ago

Kiora Pharmaceuticals Presents In Vivo Preclinical Data at ARVO 2025 Demonstrating the Potential of KIO-104 to Treat Proliferative Vitreoretinopathy Kiora Pharmaceuticals (NASDAQ: KPRX) presented promising preclinical data for KIO-104, their novel DHODH inhibitor, at ARVO 2025. The study demonstrated significant reduction in scar formation for treating proliferative vitreoretinopathy (PVR), the leading complication following retinal detachment surgery. Key findings from the rabbit model study showed: The high dose group (10 μg/eye) completely prevented scar formation in all subjects. The low dose group (1 μg/eye) showed reduced scar formation with only 9 retinal scars in 2 of 6 rabbits, with mean scar length of 43 ± 16 μm. The control group developed 20 retinal scars in 4 of 6 animals, with mean scar length of 110 ± 28 μm. KIO-104 is currently in Phase 2 clinical trials for macular edema treatment in patients with diabetic retinopathy and posterior non-infectious uveitis.

#KPRX Kiora Pharmaceuticals Presents In Vivo Preclinical Data at ARVO 2025 Demonstrating the Potential of KIO-104 to Treat Proliferative Vitreoretinopathy

www.stocktitan.net/news/KPRX/kiora-pharmace...

StockTitan

@stocktitan.net

1 year ago

Patent Victory: Kiora's Eye Drug Gets 20-Year Protection, Phase 2 Trial Coming in 2025 Kiora secures important US patent for KIO-104's crystalline form, enhancing drug stability and manufacturing potential. Phase 2 trial for macular edema set for 2025.

#KPRX Kiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104

www.stocktitan.net/news/KPRX/kiora-pharmace...

StockTitan

@stocktitan.net

1 year ago

Kiora's Game-Changing Eye Treatment Advances: Phase 2 Trial to Challenge Current Macular Edema Standards Kiora Pharmaceuticals receives green light for KLARITY trial, testing innovative T-cell suppressing therapy KIO-104 for retinal macular edema treatment.

#KPRX Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema

www.stocktitan.net/news/KPRX/kiora-receives...

Market Wire News

@marketwirenews.com

1 year ago

NEWS: ( NASDAQ: #KPRX ) Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies

#StockMarket #News